Brine Medical complies with the U.S. Food and Drug Administration (FDA) regulations governing the development, testing, and approval of pharmaceutical products. We maintain comprehensive records and adhere to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) to ensure the safety, efficacy, and quality of our therapies.

Our marine bioprospecting activities are conducted in compliance with all relevant environmental laws and international treaties. We follow the Nagoya Protocol on Access and Benefit-sharing to ensure fair and equitable sharing of benefits arising from the utilization of genetic resources.

Brine Medical ensures that all participants in our clinical trials provide informed consent. Participants are fully informed about the nature, purpose, potential risks, and benefits of the research, in accordance with the principles of the Declaration of Helsinki and the Belmont Report.

We are committed to the humane treatment of animals used in our research. Our practices comply with the Animal Welfare Act and the guidelines set forth by the Institutional Animal Care and Use Committee (IACUC), ensuring that all animal research is conducted ethically and responsibly.

We produce detailed annual reports that provide comprehensive information on our financial performance, research milestones, and strategic initiatives. These reports are available upon request and are designed to ensure full transparency and accountability to our stakeholders.

Brine Medical registers all clinical trials with ClinicalTrials.gov and other relevant databases in compliance with the International Committee of Medical Journal Editors (ICMJE) guidelines. We ensure timely disclosure of study designs, methodologies, and results to maintain transparency and public trust.

Brine Medical actively secures intellectual property rights for its innovations through the filing of patents with the United States Patent and Trademark Office (USPTO) and other international patent offices. Our patent portfolio includes several marine-derived compounds and their isolation and synthesis methods, providing robust protection for our proprietary technologies.

We engage in strategic licensing agreements that allow us to collaborate with other entities to co-develop and commercialize new therapies. These agreements are structured to ensure compliance with all relevant legal and regulatory requirements and to maximize the value of our intellectual property.